About FGH BIOTECH, INC.
FGH BioTech develops novel small molecule drugs targeting SREBP transcription factors and related pathways for the prevention and treatment of metabolic diseases and cancer. The company is driven by over 60 years of research in fat and energy metabolism by its founders.
Development of small molecule drugsTargeting SREBP transcription factors and related pathwaysResearch in fat and energy metabolism
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to FGH BIOTECH, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.